Natural Killer (NK) Cell Therapeutics Market : Opportunities and Challenges in Latest Research Report for Business Growth| Affimed GmbH, Zelluna Immunotherapy, Nektar Therapeutics, XNK Therapeutics AB, ONK Therapeutics, Catarman Bio, MiNK Therapeutics

Global Natural Killer (NK) Cell Therapeutics Market: Investment & Growth Opportunity Analysis, 2019-2028

Market Introduction

The Global Natural Killer (NK) Cell Therapeutics market is estimated to grow at a robust CAGR of 51.8% during the forecast period of 2022-2028. The market growth is attributed to the increasing interest of the pharmaceutical industry players in cellular immunotherapy. NK cell therapeutics is anticipated to witness robust growth during the forecast period owing to its ability to fulfil unmet medical needs, overcome limitations associated with existing immunotherapies, and address complex and challenging targets.
The recent increase in the number of approvals received for cancer immunotherapies is considered to have added value to the NK cell therapeutic market. Moreover, market players are making efforts for the development of novel NK cell therapies which further gives a boost to the growth of the market. For instance, Under the agreement, Gilead would receive an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy program, DF7001. DF7001 is a TriNKET designed to activate and direct NK and cytotoxic T cell killing against cancer cells. The target of DF7001 is 5T4, a protein expressed on cancer cells and stromal cells that support tumor growth associated with poor prognosis in several cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, and head and neck squamous cell carcinomas (HNSCC).

Request Sample Copy @ https://www.themarketinsights.com/request-sample/265163

Market Segmentation

The global NK cell therapeutics market has been analyzed on the basis of application, end user, and region. On the basis of application, the market is segmented into Cancer, Gastrointestinal Diseases, Immunoproliferative Disorders, and Others. Cancer segment is expected to dominate the global market. Based on end user, the market is divided into hospitals and research centers & institutes. Geographically, the market is segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and Middle East & Africa. North America is dominating the global NK cell therapeutics market.

Check for Discount @ https://www.themarketinsights.com/check-discount/265163

Market Structure and Competitive Landscape
Some of the prominent players that contribute significantly to the growth of the global NK cell therapeutics market include Nkarta, Inc,
Bristol-Myers Squibb Company,
Takeda Pharmaceutical Company Limited,
Affimed GmbH,
Zelluna Immunotherapy,
Nektar Therapeutics,
XNK Therapeutics AB,
ONK Therapeutics,
Catarman Bio,
MiNK Therapeutics,
Celularity Inc.,
Artiva Biotherapeutics
and others. These players adopt various strategies to reinforce their market share and gain a competitive edge over other competitors in the market. Partnerships and collaborations, research & development, and product launches are some of the strategies followed by industry players. Some of the key developments in the global NK cell therapeutics market include,
In August 2022, Zelluna Immunotherapy announced an investment from Takeda Ventures, Inc. (TVI), the strategic investing arm of Takeda. TVI investment joins Zelluna s latest financing round. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical Trial Application (CTA) / Investigational New Drug Application (IND) readiness and, continue the advancement of Zelluna s platform with additional programs reaching the preclinical stage.
In January 2022, Takeda announced to acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta ( ) T Cell Engager Therapies Targeting Solid Tumors. Through the acquisition, Takeda would obtain Adaptate s antibody-based T cell engager platform, including pre-clinical candidate and discovery pipeline programs.

Report Customization available as per requirements @ https://www.themarketinsights.com/request-customization/265163

Table of Content

Chapter One: Market Introduction
1.1. Scope of Study
1.2. Problem Statement
1.3. Market Segmentation
Chapter Two: Assumptions and Acronyms
Chapter Three: Executive Summary
3.1. Global Market in2022
3.2. Analyst Insights & Recommendations
3.3. Growth Opportunities and Key Strategies
3.4. Supply-side and Demand-side Trends
Chapter Four: Research Methodology
Chapter Five: Analysis of COVID-19 Impact and Road Ahead
Chapter Six: Market Indicators and Background
6.1. Macro-Economic Factors
6.2. Forecasting Factors
Robust assessment of various factors including industrial performance, healthcare expenditures, industry players expenditures, economic conditions, among others
6.3. Supply Chain & Value Chain Analysis
6.4. Industry SWOT Analysis
6.5. PESTLE Analysis
6.6. Porter s Five Forces Analysis
Chapter Seven: Government Laws and Industry Regulations
Chapter Eight: Global and Regional Market Dynamics
8.1. Drivers
8.2. Restraints
8.3. Trends
8.4. Opportunities
Chapter Nine: Global NK Cell Therapeutics Market: Key Investment Analysis
9.1. By Key Industry Players
9.2. By End User
9.3. By Therapeutic Application
9.4. By Region
9.5. M&A Activities
Robust assessment of major investments made by various industry players along with key therapeutic application areas, therapy type, and key region
Chapter Ten: Parent Market Overview: Global Healthcare & Life Sciences Market
Chapter Eleven: Market Developments: Cell & Gene Therapy Products
11.1. By Region
11.1.1. North America
11.1.2. Latin America
11.1.3. Western Europe
11.1.4. Eastern Europe
11.1.5. Asia Pacific
11.1.6. Middle East & Africa
Chapter Twelve: Clinical Trials Analysis
Exhaustive list of all the clinical trials sponsored by various industry players based on various cell types will be provided. Moreover, it would also categorize the trials into IND submissions, Phase I, Phase II etc.
Chapter Thirteen: Segmental Analysis
13.1. Global NK Cell Therapeutics Market by Application
13.1.1. Segment Overview
13.1.1.1. Cancer
13.1.1.2. Gastrointestinal Diseases
13.1.1.3. Immunoproliferative Disorders
13.1.1.4. Others
13.2. Global NK Cell Therapeutics Market by End User
13.2.1. Segment Overview
13.2.1.1. Hospitals
13.2.1.2. Research Centers and Institutes
13.2.1.3. Others
13.3. Global NK Cell Therapeutics Market by Region
13.3.1. North America
13.3.2. Latin America
13.3.3. Western Europe
13.3.4. Eastern Europe
13.3.5. Asia Pacific
13.3.6. Middle East & Africa
Chapter Fourteen: Regional Analysis
14.1. North America NK Cell Therapeutics Market Analysis and Forecast2019-2028
14.1.1. Regional Market Overview and Key Takeaways
14.1.2. North America NK Cell Therapeutics Market by Application
14.1.3. North America NK Cell Therapeutics Market by End User
14.1.4. North America NK Cell Therapeutics Market by Country
14.1.4.1. US
14.1.4.2. Canada
14.2. Latin America NK Cell Therapeutics Market Analysis and Forecast2019-2028
14.2.1. Regional Market Overview and Key Takeaways
14.2.2. Latin America NK Cell Therapeutics Market by Application
14.2.3. Latin America NK Cell Therapeutics Market by End User
14.2.4. Latin America NK Cell Therapeutics Market by Country
14.2.4.1. Brazil
14.2.4.2. Mexico
14.2.4.3. Rest of Latin America
14.3. Western Europe NK Cell Therapeutics Market Analysis and Forecast2019-2028
14.3.1. Regional Market Overview and Key Takeaways
14.3.2. Western Europe NK Cell Therapeutics Market by Application
14.3.3. Western Europe NK Cell Therapeutics Market by End User
14.3.4. Western Europe NK Cell Therapeutics Market by Country
14.3.4.1. Germany
14.3.4.2. UK
14.3.4.3. France
14.3.4.4. Spain
14.3.4.5. Italy
14.3.4.6. Benelux
14.3.4.7. Nordic
14.3.4.8. Rest of Western Europe
14.4. Eastern Europe NK Cell Therapeutics Market Analysis and Forecast2019-2028
14.4.1. Regional Market Overview and Key Takeaways
14.4.2. Eastern Europe NK Cell Therapeutics Market by Application
14.4.3. Eastern Europe NK Cell Therapeutics Market by End User
14.4.4. Eastern Europe NK Cell Therapeutics Market by Country
14.4.4.1. Russia
14.4.4.2. Poland
14.4.4.3. Rest of Eastern Europe
14.5. Asia Pacific NK Cell Therapeutics Market Analysis and Forecast2019-2028
14.5.1. Regional Market Overview and Key Takeaways
14.5.2. Asia Pacific NK Cell Therapeutics Market by Application
14.5.3. Asia Pacific NK Cell Therapeutics Market by End User
14.5.4. Asia Pacific NK Cell Therapeutics Market by Country
14.5.4.1. China
14.5.4.2. Japan
14.5.4.3. India
14.5.4.4. South Korea
14.5.4.5. Australia
14.5.4.6. ASEAN
14.5.4.7. Rest of Asia-Pacific
14.6. Middle East & Africa NK Cell Therapeutics Market Analysis and Forecast2019-2028
14.6.1. Regional Market Overview and Key Takeaways
14.6.2. Middle East & Africa NK Cell Therapeutics Market by Application
14.6.3. Middle East & Africa NK Cell Therapeutics Market by End User
14.6.4. Middle East & Africa NK Cell Therapeutics Market by Country
14.6.4.1. GCC
14.6.4.2. South Africa
14.6.4.3. Turkey
14.6.4.4. Rest of the Middle East & Africa
Chapter Fifteen: Competitive Landscape
15.1. Competition Dashboard
15.1.1. Global and Regional Market Share Analysis
15.1.2. Market Structure
15.2. Competitive Benchmarking
15.3. Key Strategy Analysis
15.4. Company Profiles
15.4.1. Affimed GmbH
15.4.1.1. Company Overview
15.4.1.2. Application/Service Offerings
15.4.1.3. Key Financials
15.4.1.4. Recent Developments
15.4.2. Bristol-Myers Squibb Company
15.4.2.1. Company Overview
15.4.2.2. Application/Service Offerings
15.4.2.3. Financials
15.4.2.4. Recent Developments
15.4.3. Nkarta Inc.
15.4.3.1. Company Overview
15.4.3.2. Application/Service Offerings
15.4.3.3. Financials
15.4.3.4. Recent Developments
15.4.4. Zelluna Immunotherapy AS
15.4.4.1. Company Overview
15.4.4.2. Application/Service Offerings
15.4.4.3. Financials
15.4.4.4. Recent Developments
15.4.5. XNK Therapeutics AB
15.4.5.1. Company Overview
15.4.5.2. Application/Service Offerings
15.4.5.3. Financials
15.4.5.4. Recent Developments
15.4.6. ONK Therapeutics
15.4.6.1. Company Overview
15.4.6.2. Application/Service Offerings
15.4.6.3. Financials
15.4.6.4. Recent Developments
15.4.7. Catamaran Bio
15.4.7.1. Company Overview
15.4.7.2. Application/Service Offerings
15.4.7.3. Financials
15.4.7.4. Recent Developments
15.4.8. MiNK Therapeutics
15.4.8.1. Company Overview
15.4.8.2. Application/Service Offerings
15.4.8.3. Financials
15.4.8.4. Recent Developments
15.4.9. Takeda Pharmaceutical Company Limited
15.4.9.1. Company Overview
15.4.9.2. Application/Service Offerings
15.4.9.3. Financials
15.4.9.4. Recent Developments
15.4.10. Celularity Inc.
15.4.10.1. Company Overview
15.4.10.2. Application/Service Offerings
15.4.10.3. Financials
15.4.10.4. Recent Developments
15.4.11. Artiva Biotherapeutics
15.4.11.1. Company Overview
15.4.11.2. Application/Service Offerings
15.4.11.3. Financials
15.4.11.4. Recent Developments
A comprehensive list of NK cell therapeutics providers will be provided along with geographical reach, employee count, revenue, product capacities, and their capabilities
Chapter Sixteen: Disclaimer

Direct Contact
Jessica Joyal
+1(213)338-8279 | +1(877)376-9989
sales@themarketinsights.com

About us.
Delivering foresights along with statistical analysis of the operational business industry impacts has been our foremost priority. With the constant developments in the research & development industry, we have always challenged the conventional research methodologies and discovered new research tactics to evolve the growing B2B requirements.

This release was published on openPR.